# Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)

> **NCT00885352** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 313 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Comparator: Placebo
- **DRUG:** Pioglitazone
- **DRUG:** Metformin
- **DRUG:** Glipizide

## Key facts

- **NCT ID:** NCT00885352
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-15
- **Primary completion:** 2010-11-10
- **Final completion:** 2010-11-10
- **Target enrollment:** 313 (ACTUAL)
- **Last updated:** 2017-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00885352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00885352, "Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00885352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*